• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Transient Viremia in Young Adults With HIV After the Switch to Long-Acting Cabotegravir and Rilpivirine: Considerations for Dosing Schedule and Monitoring.

作者信息

Rakhmanina Natella, Richards Kristen, Adeline Koay Wei Li

机构信息

Division of Infectious Diseases, Children's National Hospital, Washington, DC.

School of Medicine and Health Sciences, The George Washington University, Washington, DC; and.

出版信息

J Acquir Immune Defic Syndr. 2023 Mar 1;92(3):e14-e17. doi: 10.1097/QAI.0000000000003142.

DOI:10.1097/QAI.0000000000003142
PMID:36480701
Abstract
摘要

相似文献

1
Transient Viremia in Young Adults With HIV After the Switch to Long-Acting Cabotegravir and Rilpivirine: Considerations for Dosing Schedule and Monitoring.转换为长效卡博特韦和利匹韦林后，HIV 青年成人中的短暂病毒血症：给药方案和监测的考量
J Acquir Immune Defic Syndr. 2023 Mar 1;92(3):e14-e17. doi: 10.1097/QAI.0000000000003142.
2
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.长效肌内注射卡替拉韦和利匹韦林治疗成人 HIV-1 感染（LATTE-2）：一项随机、开放标签、2b 期、非劣效性试验的 96 周结果。
Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.
3
Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report.长效卡博特韦-利匹韦林组合用于病毒血症可检测的HIV感染者的真实生活体验：一例病例报告
AIDS Res Hum Retroviruses. 2024 Oct;40(10):555-556. doi: 10.1089/AID.2023.0057. Epub 2024 Feb 2.
4
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.长效卡博特韦和利匹韦林每 2 个月给药 1 次用于治疗 HIV-1 感染成人（ATLAS-2M）：48 周结果：一项随机、多中心、开放标签、3b 期、非劣效性研究。
Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9.
5
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.长效卡替拉韦/利匹韦林用于需要注射用抗逆转录病毒治疗的 HIV-1 感染者的同情用药。
HIV Med. 2023 Feb;24(2):202-211. doi: 10.1111/hiv.13370. Epub 2022 Aug 9.
6
Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation.用于HIV-1治疗的长效卡博特韦/利匹韦林：实施障碍的真实世界评估
AIDS. 2023 Mar 15;37(4):689-691. doi: 10.1097/QAD.0000000000003476.
7
Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.每月注射用卡替拉韦/利匹韦林治疗成人 HIV 感染。
J Am Assoc Nurse Pract. 2022 Jul 1;34(7):918-923. doi: 10.1097/JXX.0000000000000729.
8
Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine.转换为长效卡博特韦和rilpivirine后病毒学失败病例的特征分析。
J Antimicrob Chemother. 2024 Aug 1;79(8):2074-2076. doi: 10.1093/jac/dkae187.
9
HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program.长效卡博特韦/rilpivirine起始治疗方案中的HIV病毒学应答和基线基因型耐药性
AIDS. 2023 Aug 1;37(10):1641-1642. doi: 10.1097/QAD.0000000000003590.
10
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment.符合治疗条件的HIV感染者每两个月使用长效卡博特韦和rilpivirine的倾向。
J Med Virol. 2023 Jan;95(1):e28330. doi: 10.1002/jmv.28330.

引用本文的文献

1
The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections.利匹韦林探寻治疗HIV感染神奇药物的曲折之路。
Viruses. 2025 Jul 8;17(7):959. doi: 10.3390/v17070959.
2
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.长效注射用卡博特韦与长效注射用利匹韦林联合用于病毒学抑制的青少年HIV感染者的安全性研究（IMPAACT 2017/MOCHA）：一项1/2期、多中心、开放标签、非对照、剂量探索性研究
Lancet HIV. 2025 Mar;12(3):e191-e200. doi: 10.1016/S2352-3018(24)00344-8.
3
Barriers and facilitators to equitable implementation of long-acting ART for adolescents and youth with HIV in low- and middle-income settings.
低收入和中等收入环境中为感染艾滋病毒的青少年公平实施长效抗逆转录病毒疗法的障碍与促进因素
Pan Afr Med J. 2024 Oct 23;49:53. doi: 10.11604/pamj.2024.49.53.45322. eCollection 2024.